Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06338657 · ClinicalTrials.gov registry record · Phase 1
FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06338657 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 1 participants.
The verdict
NCT06338657, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma. The active drug in FID-007 is paclitaxel, an established chemotherapy drug that has been shown to kill cancer cells. FID-007 is a packaged form of paclitaxel using a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller. This study is being done to help identify future treatment options and better understand how to improve outcomes of patients with head and neck cancers after surgery.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- DRUG PEOX-based Polymer Encapsulated Paclitaxel FID-007
- PROCEDURE Tumor Resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06338657
The ClinicalTrials.gov registry entry for NCT06338657 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06338657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06338657 about?
NCT06338657 is a clinical study titled "FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer". This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma. The active drug in FID-007 is paclitaxel, an established chemotherapy drug that has been shown to kill can...
What is the current status of trial NCT06338657?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-04-01. Estimated completion is 2025-09-09.
What interventions are being tested in trial NCT06338657?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), PEOX-based Polymer Encapsulated Paclitaxel FID-007 (DRUG), Tumor Resection (PROCEDURE).
Who is sponsoring clinical trial NCT06338657?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.